You are here: Industry Insights > Tecentriq

News List

US FDA grants priority review to Roche’s Tecentriq as adjuvant treatment for non-small cell lung cancer expresspharma
August 04, 2021
Tecentriq is the first and only cancer immunotherapy to demonstrate positive phase-III results in the adjuvant lung cancer setting.
Roche records 8% increase in group sales for H1 2021 pharmaceutical-technology
July 26, 2021
Roche has reported an 8% increase in group sales to $33.46bn (CHF30.71bn) at constant exchange rates (CER) in the first half (H1) of 2021, as against $31.81bn (CHF29.28bn) in H1 last year.
Tecentriq, Kesimpta lead latest SMC decisions pharmatimes
July 14, 2021
The Scottish Medicines Consortium (SMC) has accepted three new medicines for use by NHS Scotland and rejected one in its July 2021 decisions.
NICE recommends Tecentriq for first-line NSCLC pharmatimes
June 09, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer (NSCLC).
Tecentriq approved for first-line metastatic NSCLC pharmatimes
May 07, 2021
Roche’s checkpoint inhibitor Tecentriq has gained a new approval from the European Commission, for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC), its fourth indication in this cancer type.
Roche reports 3% increase in group sales in first quarter of 2021 pharmaceutical-technology
April 23, 2021
Roche has reported a 3% increase in group sales to $16.247bn (CHF14.9bn) in the first quarter of 2021 at constant exchange rates.
Immuno-oncology to be a dominant class of drugs for hepatocellular carcinoma by 2029: GlobalData expresspharma
April 23, 2021
Class-wide sales of IO are expected to grow to 72.2 per cent of the market, contributing $3.8 billion to global sales in 2029 and growing at a CAGR of 28 per cent.
Early promise for new immunotherapy combo in brain cancer pharmatimes
April 13, 2021
A combination treatment consisting of an experimental cancer drug – ipatasertib – and Roche’s immunotherapy agent Tecentriq (atezolizumab) has demonstrated early promise in an aggressive type of brain cancer.
Roche’s Tecentriq improves disease-free survival in early lung cancer pharmatimes
March 22, 2021
Roche’s PD-L1 inhibitor Tecentriq significantly improved disease-free survival (DFS) in patients with resectable, early stage non-small cell lung cancer (NSCLC), according to newly published Phase III data.
Roche to withdraw US indication for Tecentriq in bladder cancer pharmaceutical-technolog
March 10, 2021
Roche is set to voluntarily withdraw the US indication for Tecentriq (atezolizumab) in prior platinum treated metastatic urothelial carcinoma (mUC, bladder cancer) following its consultation with the US Food and Drug Administration (FDA).

Previous page 1 2 3 4 5 6 7 Next page